Mirtazapine: A review of its clinical efficacy and tolerability

Expert Opinion on Pharmacotherapy

Volumn 6, Issue 4, 2005, Pages 631-641

  Szegedi, Armin ^a   Schwertfeger, Natascha ^a  

^a CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

AMFEBUTAMONE; AMITRIPTYLINE; CITALOPRAM; CLOMIPRAMINE; CLOZAPINE; DESIPRAMINE; DIAZEPAM; DOXEPIN; FLUOXETINE; IMIPRAMINE; LITHIUM; MAPROTILINE; MIANSERIN; MIRTAZAPINE; OLANZAPINE; PAROXETINE; PLACEBO; RISPERIDONE; SEROTONIN 2 RECEPTOR; SEROTONIN 3 RECEPTOR; SERTRALINE; TRAZODONE; VENLAFAXINE;

AGRANULOCYTOSIS; ALCOHOLISM; BINDING AFFINITY; BONE MARROW TOXICITY; CLINICAL TRIAL; CONSTIPATION; DIZZINESS; DROWSINESS; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG DETERMINATION; DRUG EFFICACY; DRUG ELIMINATION; DRUG HALF LIFE; DRUG HYPERSENSITIVITY; DRUG METABOLISM; DRUG OVERDOSE; DRUG RECEPTOR BINDING; DRUG RESPONSE; DRUG TOLERABILITY; DRUG TRANSFORMATION; DRUG URINE LEVEL; DYSTHYMIA; EJACULATION DISORDER; FACE EDEMA; HEADACHE; HUMAN; INCREASED APPETITE; MAINTENANCE THERAPY; MAJOR DEPRESSION; MONOTHERAPY; MYELODYSPLASIA; NEUROTRANSMISSION; NEUTROPENIA; ORGASM DISORDER; ORTHOSTATIC HYPOTENSION; PANIC; POSTTRAUMATIC STRESS DISORDER; REVIEW; SCHIZOPHRENIA; SEDATION; SIDE EFFECT; SOCIAL PHOBIA; TACHYCARDIA; VISUAL IMPAIRMENT; WEIGHT GAIN; XEROSTOMIA;

ANTIDEPRESSIVE AGENTS; CLINICAL TRIALS; DEPRESSIVE DISORDER, MAJOR; HUMANS; MENTAL DISORDERS; MIANSERIN; SEROTONIN ANTAGONISTS;

EID: 18144372418     PISSN: 14656566     EISSN: None     Source Type: Journal    
DOI: 10.1517/14656566.6.4.631     Document Type: Review

References (98)

1. ANGST J: The epidemiology of depressive disorders. Eur. Neuropsychopharmacol. (1995) 5(Suppl.):95-98.
2. MURRAY CJ, LOPEZ AD: Alternative projections of mortality and disability by cause 1990-2020: Global Burden of Disease Study. Lancet (1997) 349(9064):1498-1504.
3. MURRAY CJ, LOPEZ AD: Global mortality, disability, and the contribution of risk factors: Global Burden of Disease Study. Lancet (1997) 349(9063):1436-1442.
4. DE BOER TH, MAURA G, RAITERI M, DE VOS CJ, WIERINGA J, PINDER RM: Neurochemical and autonomic pharmacological profiles of the 6-aza-analogue of mianserin, Org 3770 and its enantiomers. Neuropharmacology (1988) 27(4):399-408.
5. DE BOER T, RUIGT GS: The alpha2 selective adrenoceptor antagonist Org 3770 (mirtazapine, Remeron) enhances noradrenergic and serotonergic transmission. Hum. Psychopharmacol. (1995) 10(Suppl. 2):S107-S118.
6. DE BOER T, RUIGT GS: The selective alpha2-adrenoceptor antagonist mirtazapine (Org 3779) enhances noradrenergic and 5-HT1A-mediated serotonergic neurotransmission. CNS Drugs (1995) 4(Suppl. 1):S29-S38.
7. DE BOER T: The effects of mirtazapine on central noradrenergic and serotonergic neurotransmission. Int. Clin. Psychopharmacol. (1995) 10(Suppl. 4):19-23.
8. DEMONTIGNY C, HADDJERI N, MONGEAU R et al.: The effects of mirtazapine on the interactions between acute and long-term actions of mirtazapine. CNS Drugs (1995) 4:S13-S17.
9. HADDJERI N, BLIER P, DE MONTIGNY C: Noradrenergic modulation of central serotonergic neurotransmission: acute and long-term actions of mirtazapine. Int. Clin. Psychopharmacol. (1995) 10(Suppl. 4):11-17.
10. HADDJERI N, BLIER P, DE MONTIGNY C: Acute and long-term actions of the antidepressant drug mirtazapine on central 5-HT neurotransmission. J. Affect. Disord. (1998) 51(3):255-266.
11. RADHAKISHUN FS, VAN DEN BOS J, VAN DER HEIJDEN BC, ROES KC, O'HANLON JF: Mirtazapine effects on alertness and sleep in patients as recorded by interactive telecommunication during treatment with different dosing regimens. J. Clin. Psychopharmacol. (2000) 20(5):531-537.
12. GOWER AJ, BROEKKAMP CL, RIJK HW, VAN DELFT AM: Pharmacological evaluation of in vivo tests for alpha 2-adrenoceptor blockade in the central nervous system and the effects of the enantiomers of mianserin and its aza-analog ORG 3770. Arch. Int. Pharmacodyn. Ther. (1988) 291:185-201.
13. MCGRATH C, BURROWS GD, NORMAN TR: Neurochemical effects of the enantiomers of mirtazapine in normal rats. Eur. J. Pharmacol. (1998) 356(2-3):121-126.
14. COHEN M, PANAGIDES J, TIMMER CJ, HUISMAN JA: Pharmacokinetics of mirtazapine from orally administered tablets: influence of a high-fat meal. Eur. J. Drug Metab. Pharmacokinet. (1997) 22(2):103-110.
15. VOORTMAN G, PAANAKKER JE: Bioavailability of mirtazapine from Remeron tablets after single and multiple oral dosing. Hum. Psychopharmacol. (1995) 10(Suppl. 2):S83-S96.
16. TIMMER CJ, A.A.M. L, C.P.A. M: Pharmacokinetic dose-proportionality study at steady state of mirtazapine from Remeron tablets. Hum. Psychopharmacol. (1995) 10(Suppl. 2):S97-106.
17. STORMER E, VON MOLTKE LL, SHADER RI, GREENBLATT DJ: Metabolism of the antidepressant mirtazapine in vitro: contribution of cytochromes P450 1A2, 2D6, and 3A4. Drug Metab. Dispos. (2000) 28(10):1168-1175.
18. DODD S, BOULTON DW, BURROWS GD, DE VANE CL, NORMAN TR: In vitro metabolism of mirtazapine enantiomers by human cytochrome P450 enzymes. Hum. Psychopharmacol. (2001) 16(7):541-544.
19. PRESKORN SH: Selection of an antidepressant: mirtazapine. J. Clin. Psychiatry (1997) 58(Suppl. 6):3-8.
20. DELBRESSINE LP, VOS RM: The clinical relevance of preclinical data: mirtazapine, a model compound. J. Clin. Psychopharmacol. (1997) 17(Suppl. 1):29S-33S.
21. SHAMS M, HIEMKE C, HARTTER S: Therapeutic drug monitoring of the antidepressant mirtazapine and its N-demethylated metabolite in human serum. Ther. Drug Monit. (2004) 26(1):78-84.
22. KIRCHHEINER J, HENCKEL HB, MEINEKE I, ROOTS I, BROCKMOLLER J: Impact of the CYP2D6 ultrarapid metabolizer genotype on mirtazapine pharmacokinetics and adverse events in healthy volunteers. J. Clin. Psychopharmacol. (2004) 24(6):647-652.
23. DAHL ML, VOORTMAN G, ALM C: In vitro and in vivo studies on the disposition of mirtazapine in humans. Clin. Drug Invest. (1997) 13:37-46.
24. BREMNER JD: A double-blind comparison of Org 3770, amitriptyline, and placebo in major depression. J. Clin. Psychiatry (1995) 56(11):519-525.
25. CLAGHORN JL, LESEM MD: A double-blind placebo-controlled study of Org 3770 in depressed outpatients. J. Affect. Disord. (1995) 34(3):165-171.
26. HALIKAS JA: Org 3770 (mirtazapine) versus trazodone: a placebo-controlled trial in depressed elderly patients. Hum. Psychopharmacol. (1995) 10:125s-133s.
27. KHAN MC: A randomized, double-blind, placebo-controlled 5-weeks study of Org 3770 (mirtazapine) in major depression. Hum. Psychopharmacol. (1995) 10:119s-124s.
28. SMITH WT, GLAUDIN V, PANAGIDES J, GILVARY E: Mirtazapine versus amitriptyline versus placebo in the treatment of major depressive disorder. Psychopharmacol. Bull. (1990) 26(2):191-196.
29. VARTIAINEN H, LEINONEN E: Double-blind study of mirtazapine and placebo in hospitalized patients with major depression. Eur. Neuropsychopharmacol. (1994) 4(2):145-150.
30. BECH P: Meta-analysis of placebo-controlled trials with mirtazapine using the core items of the Hamilton Depression Scale as evidence of a pure antidepressive effect in the short-term treatment of major depression. Int. J. Neuropsychopharmacol. (2001) 4(4):337-345.
31. HOYBERG OJ, MARAGAKIS B, MULLIN J et al.: A double-blind multicentre comparison of mirtazapine and amitriptyline in elderly depressed patients. Acta Psychiatr. Scand. (1996) 93(3):184-190.
32. MULLIN J, LODGE A, BENNIE E, MCCREADIE R, BHATT GS, FENTON G: A multicentre, double-blind, amitriptyline-controlled study of mirtazapine in patients with major depression. J. Psychopharmacol. (1996) 10:235-240.
33. ZIVKOV M, DEJONGH GD: Org 3770 versus amitriptyline: a 6-week randomized double-blind multicentre trial in hospitalized depressed patients. Hum. Psychopharmacol. (1995) 10:S173-S180.
34. STAHL S, ZIVKOV M, REIMITZ PE, PANAGIDES J, HOFF W: Meta-analysis of randomized, double-blind, placebo-controlled, efficacy and safety studies of mirtazapine versus amitriptyline in major depression. Acta Psychiatr. Scand. Suppl. (1997) 391:22-30.
35. RICHOU H, RUIMY P, CHARBAUT J et al.: A multicentre, double-blind, clomipramine-controlled efficacy and safety study of Org 3770. Hum. Psychopharmacol. (1995) 10:263-271.
36. MARTTILA M, JAASKELAINEN J, JARVI R et al.: A double-blind study comparing the efficacy and tolerability of mirtazapine and doxepin in patients with major depression. Eur. Neuropsychopharmacol. (1995) 5(4):441-446.
37. BRUIJN JA, MOLEMAN P, MULDER PG et al.: A double-blind, fixed blood-level study comparing mirtazapine with imipramine in depressed in-patients. Psychopharmacology (Berl) (1996) 127(3):231-237.
38. VAN MOFFAERT M, DE WILDE J, VEREECKEN A et al.: Mirtazapine is more effective than trazodone: a double-blind controlled study in hospitalized patients with major depression. Int. Clin. Psychopharmacol. (1995) 10(1):3-9.
39. WHEATLEY DP, VAN MOFFAERT M, TIMMERMAN L, KREMER CM: Mirtazapine: efficacy and tolerability in comparison with fluoxetine in patients with moderate to severe major depressive disorder. Mirtazapine-Fluoxetine Study Group. J. Clin. Psychiatry (1998) 59(6):306-312.
40. HONG CJ, HU WH, CHEN CC, HSIAO CC, TSAI SJ, RUWE FJ: A double-blind, randomized, group-comparative study of the tolerability and efficacy of 6 weeks' treatment with mirtazapine or fluoxetine in depressed Chinese patients. J. Clin. Psychiatry (2003) 64(8):921-926.
41. LEINONEN E, SKARSTEIN J, BEHNKE K, AGREN H, HELSDINGEN JT: Efficacy and tolerability of mirtazapine versus citalopram: a double-blind, randomized study in patients with major depressive disorder. Nordic Antidepressant Study Group. Int. Clin. Psychopharmacol. (1999) 14(6):329-337.
42. BENKERT O, SZEGEDI A, KOHNEN R: Mirtazapine compared with paroxetine in major depression. J. Clin. Psychiatry (2000) 61(9):656-663.
43. WADE A, CRAWFORD GM, ANGUS M, WILSON R, HAMILTON L: A randomized, double-blind, 24-week study comparing the efficacy and tolerability of mirtazapine and paroxetine in depressed patients in primary care. Int. Clin. Psychopharmacol. (2003) 18(3):133-141.
44. SCHATZBERG AF, KREMER C, RODRIGUES HE, MURPHY GM, Jr.: Double-blind, randomized comparison of mirtazapine and paroxetine in elderly depressed patients. Am. J. Geriatr. Psychiatry (2002) 10(5):541-550.
45. BEHNKE K, SOCAARD J, MARTIN S et al.: Mirtazapine orally disintegrating tablet versus sertraline: a prospective onset of action study. J. Clin. Psychopharmacol. (2003) 23(4):358-364.
46. THASE ME, KREMER C, RODRIGUES H: Mirtazapine versus sertraline after SSRI-nonresponse. Results of a double-blind switch study. Eur. Neuropsychopharmacol. (2001) 11(Suppl. 3):S342.
47. GUELFI JD, ANSSEAU M, TIMMERMAN L, KORSGAARD S: Mirtazapine versus venlafaxine in hospitalized severely depressed patients with melancholic features. J. Clin. Psychopharmacol. (2001) 21(4):425-431.
48. SZEGEDI A, PHILIPP M, BENKERT O et al.: More rapid onset of antidepressant effect with mirtazapine fast dissolving tablets (FDT) versus venlafaxine extended release (XR): a randomized, double-blind study. Poster presented at the ECNP Meeting. Stockholm, Sweden (2004).
49. MONTGOMERY SA, REIMITZ PE, ZIVKOV M: Mirtazapine versus amitriptyline in the long-term treatment of depression: a double-blind placebo-controlled study. Int. Clin. Psychopharmacol. (1998) 13(2):63-73.
50. THASE ME, NIERENBERG AA, KELLER MB, PANAGIDES J: Efficacy of mirtazapine for prevention of depressive relapse: a placebo-controlled double-blind trial of recently remitted high-risk patients. J. Clin. Psychiatry (2001) 62(10):782-788.
51. CARPENTER LL, YASMIN S, PRICE LH: A double-blind, placebo-controlled study of antidepressant augmentation with mirtazapine. Biol. Psychiatry (2002) 51(2):183-188.
52. STAHL SM: Are two antidepressant mechanisms better than one? J. Clin. Psychiatry (1997) 58(8):339-340.
53. DE BOER T, NEFKENS F, VAN HELVOIRT A: The alpha 2-adrenocepror antagonist Org 3770 enhances serotonin transmission in vivo. Eur. J. Pharmacol. (1994) 253(1-2):R5-R6.
54. SZEGEDI A, MULLER MJ, ANGHELESCU I, KLAWE C, KOHNEN R, BENKERT O: Early improvement under mirtazapine and paroxetine predicts later stable response and remission with high sensitivity in patients with major depression. J. Clin. Psychiatry (2003) 64(4):413-420.
55. RIBEIRO L, BUSNELLO JV, KAUER-SANT'ANNA M et al.: Mirtazapine versus fluosetine in the treatment of panic disorder. Braz J. Med. Biol. Res. (2001) 34(10):1303-1307.
56. BOSHUISEN ML, SLAAP BR, VESTER-BLOKLAND ED, DEN BOER JA: The effect of mirtazapine in panic disorder: an open label pilot study with a single-blind placebo run-in period. Int. Clin. Psychopharmacol. (2001) 16(6):363-368.
57. CARLI V, SARCHIAPONE M, CAMARDESE G, ROMANO L, DERISIO S: Mirtazapine in the treatment of panic disorder. Arch. Gen. Psychiatry (2002) 59(7):661-662.
58. SARCHIAPONE M, AMORE M, DE RISIO S et al.: Mirtazapine in the treatment of panic disorder: an open-label trial. Int. Clin. Psychopharmacol. (2003) 18(1):35-38.
59. DAVIDSON JR, WEISLER RH, BUTTERFIELD MI et al.: Mirtazapine versus placebo in posttraumatic stress disorder: a pilot trial. Biol. Psychiatry (2003) 53(2):188-191.
60. CONNOR KM, DAVIDSON JR, WEISLER RH, AHEARN E: A pilot study of mirtazapine in post-traumatic stress disorder. Int. Clin. Psychopharmacol. (1999) 14(1):29-31.
61. BAHK WM, PAE CU, TSOH J et al.: Effects of mirtazapine in patients with posttraumatic stress disorder in Korea: a pilot study. Hum. Psychopharmacol. (2002) 17(7):341-344.
62. CHUNG MY, MIN KH, JUN YJ, KIM SS, KIM WC, JUN EM: Efficacy and tolerability of mirtazapine and sertraline in Korean veterans with posttraumatic stress disorder: a randomized open label trial. Hum. Psychopharmacol. (2004) 19(7):489-494.
63. BERK M, ICHIM C, BROOK S: Efficacy of mirtazapine add on therapy to haloperidol in the treatment of the negative symptoms of schizophrenia: a double-blind randomized placebo-controlled study. Int. Clin. Psychopharmacol. (2001) 16(2):87-92.
64. ZOCCALI R, MUSCATELLO MR, CEDRO C et al.: The effect of mirtazapine augmentation of dozapine in the treatment of negative symptoms of schizophrenia: a double-blind, placebo-controlled study. Int. Clin. Psychopharmacol. (2004) 19(2):71-76.
65. POYUROVSKY M, EPSHTEIN S, FUCHS C, SCHNEIDMAN M, WEIZMAN R, WEIZMAN A: Efficacy of low-dose mirtazapine in neuroleptic-induced akathisia: a double-blind randomized placebo-controlled pilot study. J. Clin. Psychopharmacol. (2003) 23(3):305-308.
66. DUNNER DL, HENDRICKSON HE, BEA C, BUDECH CB, O'CONNOR E: Dysthymic disorder: treatment with mirtazapine. Depress. Anxiety (1999) 10(2):68-72.
67. VAN VEEN JF, VAN VLIET IM, WESTENBERG HG: Mirtazapine in social anxiety disorder: a pilot study. Int. Clin. Psychopharmacol. (2002) 17(6):315-317.
68. LIAPPAS J, PAPARRIGOPOULOS T, TZAVELLAS E, CHRISTODOULOU G: Alcohol detoxification and social anxiety symptoms: a preliminary study of the impact of mirtazapine administration. J. Affect. Disord. (2003) 76(1-3):279-284.
69. LIAPPAS J, PAPARRIGOPOULOS T, TZAVELLAS E, RABAVILAS A: Mirtazapine and venlafaxine in the management of collateral psychopathology during alcohol detoxification. Prog. Neuropsychopharmacol. Biol. Psychiatry (2005) 29(1):55-60.
70. BENDTSEN L, JENSEN R: Mirtazapine is effective in the prophylactic treatment of chronic tension-type headache. Neurology (2004) 62(10):1706-1711.
71. BRANNON GE, STONE KD: The use of mirtazapine in a patient with chronic pain. J. Pain Symptom Manage. (1999) 18(5):382-385.
72. BRANNON GE, ROLLAND PD, GARY JM: Use of mirtazapine as prophylactic treatment for migraine headache. Psychosomatics (2000) 41(2):153-154.
73. NUTT D, LAW J: Treatment of cluster headache with mirtazapine. Headache (1999) 39(8):586-587.
74. SAMBORSKI W, LEZANSKA-SZPERA M, RYBAKOWSKI JK: Open trial of mirtazapine in patients with fibromyalgia. Pharmacopsychiatry (2004) 37(4):168-170.
75. PAHWA R, LYONS KE: Mirtazapine in essential tremor: a double-blind, placebo-controlled pilot study. Mov. Disord. (2003) 18(5):584-587.
76. ASLAN S, ISIK E, COSAR B: The effects of mirtazapine on sleep: a placebo controlled, double-blind study in young healthy volunteers. Sleep (2002) 25(6):677-679.
77. WINOKUR A, SATEIA MJ, HAYES JB, BAYLES-DAZET W, MACDONALD MM, GARY KA: Acute effects of mirtazapine on sleep continuity and sleep architecture in depressed patients: a pilot study. Biol. Psychiatry (2000) 48(1):75-78.
78. DAVIS MP, FRANDSEN JL, WALSH D, ANDRESEN S, TAYLOR S: Mirtazapine for pruritus. J. Pain Symptom Manage. (2003) 25(3):288-291.
79. THEOBALD DE, KIRSH KL, HOLTSCLAW E, DONAGHY K, PASSIK SD: An open-label, crossover trial of mirtazapine (15 and 30 mg) in cancer patients with pain and other distressing symptoms. J. Pain Symptom Manage. (2002) 23(5):442-447.
80. WALDINGER MD, BERENDSEN HH, SCHWEITZER DH: Treatment of hot flushes with mirtazapine: four case reports. Maturitas (2000) 36(3):165-168.
81. VAN DEN BRINK RH, VAN MELLE JP, HONIG A et al.: Treatment of depression after myocardial infarction and the effects on cardiac prognosis and quality of life: rationale and outline of the Myocardial INfarction and Depression-Intervention Trial (MIND-IT). Am. Heart J. (2002) 144(2):219-225.
82. MONTGOMERY SA: Safety of mirtazapine: a review. Int. Clin. Psychopharmacol. (1995) 10(Suppl. 4):37-45.
83. NICHOLAS LM, FORD AL, ESPOSITO SM, EKSTROM RD, GOLDEN RN: The effects of mirtazapine on plasma lipid profiles in healthy subjects. J. Clin. Psychiatry (2003) 64(8):883-889.
84. NELSON JC: Safety and tolerability of the new antidepressants. J. Clin. Psychiatry (1997) 58(Suppl. 6):26-31.
85. BISWAS PN, WILTON LV, SHAKIR SA: The pharmacovigilance of mirtazapine: results of a prescription event monitoring study on 13554 patients in England. J. Psychopharmacol. (2003) 17(1):121-126.
86. WESTENBERG HG: Pharmacology of antidepressants: selectivity or multiplicity? J. Clin. Psychiatry (1999) 60(Suppl. 17):4-8; discussion 46-48.
87. MONTEJO AL, LLORCA G, IZQUIERDO JA, RICO-VILLADEMOROS F: Incidence of sexual dysfunction associated with antidepressant agents: a prospective multicenter study of 1022 outpatients. Spanish Working Group for the Study of Psychotropic-Related Sexual Dysfunction. J. Clin. Psychiatry (2001) 62(Suppl. 3):10-21.
88. WALDINGER MD, ZWINDERMAN AH, OLIVIER B: Antidepressants and ejaculation: a double-blind, randomized, fixed-dose study with mirtazapine and paroxetine. J. Clin. Psychopharmacol. (2003) 23(5):467-470.
89. MATTILA M, MATTILA MJ, VRIJMOED-DE VRIES M, KUITUNEN T: Actions and interactions of psychotropic drugs on human performance and mood: single doses of ORG 3770, amitriptyline, and diazepam. Pharmacol. Toxicol. (1989) 65(2):81-88.
90. LOONEN AJ, DOORSCHOT CH, OOSTELBOS MC, SITSEN JM: Lack of drug interactions between mirtazapine and risperidone in psychiatric patients: a pilot study. Eur. Neuropsychopharmacol. (1999) 10(1):51-57.
91. SITSEN JM, VOORTMAN G, TIMMER CJ: Pharmacokinetics of mirtazapine and lithium in healthy male subjects. J. Psychopharmacol. (2000) 14(2):172-176.
92. RUWE FJ, SMULDERS RA, KLEIJN HJ, HARTMANS HL, SITSEN JM: Mirtazapine and paroxetine: a drug-drug interaction study in healthy subjects. Hum. Psychopharmacol. (2001) 16(6):449-459.
93. TIMMER CJ, SITSEN JM, DELBRESSINE LP: Clinical pharmacokinetics of mirtazapine. Clin. Pharmacokinet. (2000) 38(6):461-474.
94. SITSEN J, MARIS F, TIMMER C: Drug-drug interaction studies with mirtazapine and carbamazepine in healthy male subjects. Eur. J. Drug Metab. Pharmacokinet. (2001) 26(1-2):109-121.
95. SPAANS E, VAN DEN HEUVEL MW, SCHNABEL PG et al.: Concomitant use of mirtazapine and phenytoin: a drug-drug interaction study in healthy male subjects. Eur. J. Clin. Pharmacol. (2002) 58(6):423-429.
96. ZOCCALI R, MUSCATELLO MR, TORRE DL et al.: Lack of a pharmacokinetic interaction between mirtazapine and the newer antipsychotics clozapine, risperidone and olanzapine in patients with chronic schizophrenia. Pharmacol. Res. (2003) 48(4):411-414.
97. MURPHY GM Jr, HOLLANDER SB, RODRIGUES HE, KREMER C, SCHATZBERG AF: Effects of the serotonin transporter gene promoter polymorphism on mirtazapine and paroxetine efficacy and adverse events in geriatric major depression. Arch. Gen. Psychiatry (2004) 61(11):1163-1169.
98. SZEGEDI A, RUJESCU D, TADIC A et al.: The catechol-O-methyltransferase Val(108/158) Met polymorphism affects short-term treatment response to mirtazapine, but not to paroxetine in major depression. Pharmacogenomics J. (2005) 5(1):49-53.